This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%. There are two primary study hypotheses: Hypothesis 1: Combination of calderasib and pembrolizumab is superior to placebo plus pembrolizumab with respect to progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR). Hypothesis 2: Combination of calderasib plus pembrolizumab is superior to placebo plus pembrolizumab with respect to overall survival (OS).

The purpose of this study is to answer several questions. We want to understand if the study vaccines are safe to use in people living with HIV and whether they can get the study vaccines without being too uncomfortable. We also want to understand how peoples immune systems respond to the study vaccines and whether stopping HIV medications changes these immune responses

The purpose of this research is to evaluate the tolerability of frexalimab (an investigational study drug) and its potential effectiveness to prevent graft rejection and preserve renal function over time, with potentially a reduced number of complications compared to standard of care.

A study to look at safety of GSK3862995B in patients with bronchiectasis.

Through participation in this study, UPenn will become a TrialNet Natural History Study affiliate site. TrialNet, (short title) began in 2004 and has screened over 240,000 family members for diabetes related antibodies. This specific Pathway to Prevention TrialNet study (TN-01) plans to perform baseline and repeat assessments over time in a population of adults (18+) in order to confirm immunologic status of individuals at risk for type 1 diabetes. The study is divided into a Screening and a Monitoring stage. Each stage will use a separate Informed Consent document for enrollment.